Pavia

Running trials

• Not yet recruiting

  An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy

  NCT07789483· Phase 3· Source

• Recruiting

  A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)

  NCT07624305· Phase 3· Source

• Recruiting

  Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment

  NCT07691970· Phase 3· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for Adults Participants With ATTR-CM

  NCT07608354· Phase 2· Source

• Recruiting

  A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.

  NCT07652658· Phase 2· Source

• Recruiting

  A Real-life Observational Study in Severe Eosinophilic Asthma Adult Participant Treated With Benralizumab in Italy

  NCT07214753· Source

• Recruiting

  A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

  NCT07082738· Phase 2· Source

• Recruiting

  Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure

  NCT06651970· Phase 4· Source

• Recruiting

  Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function

  NCT06307652· Phase 3· Source

• Active, not recruiting

  Study of ALXN2220 Versus Placebo in Adults With ATTR-CM

  NCT06183931· Phase 3· Source

• Recruiting

  A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy

  NCT06129864· Phase 3· Source

• Active, not recruiting

  A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.

  NCT05984277· Phase 3· Source

• Recruiting

  A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma

  NCT06023589· Phase 3· Source

• Active, not recruiting

  PASS of Paediatric Patients Initiating Selumetinib

  NCT05388370· Source

• Active, not recruiting

  Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer

  NCT03682068· Phase 3· Source

• Active, not recruiting

  To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.

  NCT03330847· Phase 2· Source

• Active, not recruiting

  Savolitinib vs. Sunitinib in MET-driven PRCC.

  NCT03091192· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Asthma2 recruiting
• Heart failure2 recruiting
• Amyloidosis1 recruiting
• Chronic kidney disease1 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• COPD1 recruiting
• Head and neck cancer1 recruiting
• Idiopathic pulmonary fibrosis1 recruiting
• Lupus (SLE)1 recruiting
• Systemic sclerosis (scleroderma)1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Outcomes in Real-life After Initation of Treatment With Trixeo (Budesonide / Glycopyrronium / Formoterol)

  NCT05862545· Source

• Completed

  Continuing Sodium Zirconium Cyclosilicate (SZC) After Discharge Study

  NCT05347693· Phase 4· Source

• Terminated

  A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia

  NCT05056727· Phase 3· Source

• Terminated

  Effect of Sodium Zirconium Cyclosilicate on Arrythmia-related Cardiovascular Outcomes in Participants on Chronic Hemodialysis With Recurrent Hyperkalemia (DIALIZE-Outcomes)

  NCT04847232· Phase 3· Source

• Completed

  Study of Durvalumab Following Radiation Therapy in Patients With Stage 3 Unresectable NSCLC Ineligible for Chemotherapy

  NCT04249362· Phase 2· Source